πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. CS-101

    The First People's Hospital of Lianyungang

    Beta-Thalassemia

    phase 1 mab completed

    1 trial

  2. CT-996

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  3. CTA101

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  4. CVA

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  5. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  6. Chinese Herbal Compound Ointment

    The First People's Hospital of Lianyungang

    Atrophic Vaginitis

    phase 1 small molecule active

    1 trial

  7. ClinOleic (Baxter Healthcare, Deerfield, IL, USA)

    The First People's Hospital of Lianyungang

    Nutritional Supplement Toxicity

    phase 1 small molecule active

    1 trial

  8. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

  9. Dexlansoprazole Injection

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule active

    1 trial

  10. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Heart Injuries

    phase 1 small molecule active

    1 trial

  11. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Cesarean Section, Affecting Fetus or Newborn

    phase 1 small molecule completed

    1 trial

  12. Digoxin

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule completed

    1 trial

  13. Eprolidone

    The First People's Hospital of Lianyungang

    Chronic Heart Failure Patients

    phase 1 small molecule active

    1 trial

  14. Esketamine injection group (0.25 mg/kg)

    The First People's Hospital of Lianyungang

    Esketamine

    phase 1 small molecule active

    1 trial

  15. Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059οΌ‰οΌ‰

    The First People's Hospital of Lianyungang

    T2DM

    phase 1 small molecule active

    1 trial

  16. FT-003

    The First People's Hospital of Lianyungang

    Neovascular Age-related Macular Degeneration

    phase 1 gene therapy active

    1 trial

  17. FT-003

    The First People's Hospital of Lianyungang

    Diabetic Macular Edema

    phase 1 gene therapy active

    1 trial

  18. Ferric Carboxymaltose Injection

    The First People's Hospital of Lianyungang

    Healthy Adult

    phase 1 small molecule completed

    1 trial

  19. GK01 Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  20. GMCN-508B (LentiRed)

    The First People's Hospital of Lianyungang

    Transfusion Dependent Beta-Thalassemia

    phase 1 gene therapy active

    1 trial

  21. GPC3 and/or TGFΞ² targeting CAR-T cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  22. GPRC5D CAR-T cell intravenous infusion

    The First People's Hospital of Lianyungang

    Plasma Cell Dyscrasias

    phase 1 mab active

    1 trial

  23. GST-HG121 tablets

    The First People's Hospital of Lianyungang

    Pharmacokinetics

    phase 1 small molecule active

    1 trial

  24. Gallium-68 NODAGA-JR11

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 1 small molecule active

    1 trial

  25. HER2 Tumor Vaccine

    The First People's Hospital of Lianyungang

    Adenocarcinoma - GEJ

    phase 1 mab active

    1 trial

  26. HSK3486

    The First People's Hospital of Lianyungang

    Chronic Renal Impairment

    phase 1 small molecule completed

    1 trial

  27. HSK3486

    The First People's Hospital of Lianyungang

    Healthy Elderly Subjects

    phase 1 small molecule completed

    1 trial

  28. HY-2003 (10 mg/ml), BELKYRA and placebo

    The First People's Hospital of Lianyungang

    Moderate or Severe Submental Fullness

    phase 1 small molecule active

    1 trial

  29. Hema-NeoTIL01

    The First People's Hospital of Lianyungang

    Leukemia, Myeloid, Acute

    phase 1 mab active

    1 trial

  30. Human BCMA targeted T Cells Injection

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  31. Human Umbilical Mesenchymal Stem Cells

    The First People's Hospital of Lianyungang

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

  32. Human amniotic-derived mesenchymal stem cells

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 mab active

    1 trial

  33. Hydronidone capsules

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    phase 1 small molecule active

    1 trial

  34. IBR733 Cell Injection

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  35. ICI201

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

  36. JWCAR129

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    phase 1 mab active

    1 trial

  37. JY306 universal NK cell injection

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Hematological Malignancies

    phase 1 mab active

    1 trial

  38. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  39. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  40. Keverprazan

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    phase 1 small molecule active

    1 trial

  41. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  42. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

  43. LVIVO-TaVec200 product

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  44. LY007

    The First People's Hospital of Lianyungang

    B-NHL

    phase 1 small molecule active

    1 trial

  45. Lansoprazole capsules

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule completed

    1 trial

  46. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  47. Light Power Density and Light Duration 40 mW/cmΒ²*1000s

    The First People's Hospital of Lianyungang

    Healthy Adult Subjects

    phase 1 other completed

    1 trial

  48. Low dose ET019002- T Cells

    The First People's Hospital of Lianyungang

    B-Cell Malignancies

    phase 1 mab active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.